On May 15, 2025, Abeona Therapeutics, Inc. (ABEO) announced financial results for the first quarter of 2025 and provided a business update. Following the approval of Zevaskyn (prademagene zamikeracel) by the U.S. Food and Drug Administration (FDA) for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB), the company has activated the first qualified treatment center that will begin treating patients in the third quarter of 2025. Since the approval of Zevaskyn, approximately 30 patients and caregivers have begun registering in the Abeona Assist patient services program. Abeona also recently entered into a sales agreement for the Priority Review Voucher (PRV) it acquired as part of the approval of Zevaskyn for $155 million.
